0.26
price down icon10.34%   -0.03
after-market 시간 외 거래: .27 0.01 +3.85%
loading

Syros Pharmaceuticals Inc 주식(SYRS)의 최신 뉴스

pulisher
06:40 AM

Syros pharmaceuticals chief medical officer sells shares for $2,382 By Investing.com - Investing.com Australia

06:40 AM
pulisher
06:40 AM

Syros Pharmaceuticals chief legal officer sells $10,320 in stock By Investing.com - Investing.com Australia

06:40 AM
pulisher
06:33 AM

Syros pharmaceuticals chief medical officer sells shares for $2,382 - Investing.com India

06:33 AM
pulisher
Nov 20, 2024

Syros Pharmaceuticals CEO Chee Conley sells shares worth $26,932 - Investing.com

Nov 20, 2024
pulisher
Nov 20, 2024

Syros pharmaceuticals chief development officer sells shares for $7,949 By Investing.com - Investing.com UK

Nov 20, 2024
pulisher
Nov 20, 2024

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2024 Earnings Call Transcript - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

Brookline Capital Downgrades Syros Pharmaceuticals (SYRS) - MSN

Nov 20, 2024
pulisher
Nov 19, 2024

Syros cut to neutral by H.C. Wainwright on failed drug study - MSN

Nov 19, 2024
pulisher
Nov 18, 2024

Syros Pharmaceuticals hits record low on QIAGEN deal termination and leadership changes - XM

Nov 18, 2024
pulisher
Nov 18, 2024

Syros Pharmaceuticals Faces Financial Struggles Amid Key Challenges - TipRanks

Nov 18, 2024
pulisher
Nov 17, 2024

What is HC Wainwright’s Forecast for SYRS Q1 Earnings? - Defense World

Nov 17, 2024
pulisher
Nov 15, 2024

Avidity Partners Management LP's Strategic Acquisition in Syros Pharmaceuticals Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Blue Owl Capital Holdings LP Increases Stake in Syros Pharmaceuticals Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Syros Pharmaceuticals (NASDAQ:SYRS) Earns Neutral Rating from HC Wainwright - Defense World

Nov 15, 2024
pulisher
Nov 14, 2024

Syros Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright - Yahoo Finance

Nov 14, 2024
pulisher
Nov 14, 2024

JMP Securities cuts Syros Pharma stock rating following unsuccessful trial By Investing.com - Investing.com Australia

Nov 14, 2024
pulisher
Nov 13, 2024

Syros Pharmaceuticals' SWOT analysis: stock faces headwinds after trial setback - Investing.com Canada

Nov 13, 2024
pulisher
Nov 13, 2024

No RARA, Syros trouble: MDS phase III sinks tamibarotene - BioWorld Online

Nov 13, 2024
pulisher
Nov 13, 2024

Syros’s Hopes Dashed As Tamibarotene Flunks Phase III MDS Trial - Citeline News & Insights

Nov 13, 2024
pulisher
Nov 13, 2024

Syros Pharmaceuticals stock hits 52-week low at $0.4 By Investing.com - Investing.com Canada

Nov 13, 2024
pulisher
Nov 13, 2024

JMP Securities cuts Syros Pharma stock to Market Perform - Investing.com

Nov 13, 2024
pulisher
Nov 13, 2024

U.S. Stock market: Syros Pharmaceuticals(−86.21%), GlucoTrack(−77.70%) and others among the most volatile stocks during mid day trading - Business Upturn

Nov 13, 2024
pulisher
Nov 13, 2024

Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default - Benzinga

Nov 13, 2024
pulisher
Nov 13, 2024

Syros Pharmaceuticals downgraded to Hold from Buy at TD Cowen - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

Syros Pharmaceuticals stock hits 52-week low at $0.4 - Investing.com

Nov 13, 2024
pulisher
Nov 13, 2024

Syros stock craters after lead cancer therapy flops in Phase III trial - Pharmaceutical Technology

Nov 13, 2024
pulisher
Nov 13, 2024

U.S. Stock market: Syros Pharmaceuticals surges by 680.00% while Spirit Airlines rises by 184.96% in early trading - Business Upturn

Nov 13, 2024
pulisher
Nov 13, 2024

Syros flunks phase 3 blood cancer trial, triggering loan default and share-price plunge - Fierce Biotech

Nov 13, 2024
pulisher
Nov 13, 2024

Syros Pharmaceuticals' (SYRS) Hold Rating Reiterated at Brookline Capital Management - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Analysts Set Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Target Price at $5.00 - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

JMP Securities Reiterates Market Perform Rating for Syros Pharmaceuticals (NASDAQ:SYRS) - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Syros Pharmaceuticals' (SYRS) "Hold" Rating Reaffirmed at TD Cowen - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Syros Pharmaceuticals Shares Plummet Premarket After Study Failure - MarketWatch

Nov 13, 2024
pulisher
Nov 13, 2024

Syros Crashes Over 90% on Late-Stage MDS Fail, Loan Default - BioSpace

Nov 13, 2024
pulisher
Nov 13, 2024

TD Cowen downgrades Syros Pharma stock to Hold on trial failure - Investing.com

Nov 13, 2024
pulisher
Nov 13, 2024

Syros downgraded to Market Perform from Outperform at JMP Securities - TipRanks

Nov 13, 2024
pulisher
Nov 12, 2024

Syros stock dives 92% on failed Phase 3 study, possible loan default (update) - MSN

Nov 12, 2024
pulisher
Nov 12, 2024

Syros Pharmaceuticals trial fails to meet primary goal - Investing.com

Nov 12, 2024
pulisher
Nov 12, 2024

Syros Pharmaceuticals trial fails to meet primary goal By Investing.com - Investing.com UK

Nov 12, 2024
pulisher
Nov 12, 2024

Syros Pharma Stock Alert: Phase 3 Trial Fails, Loan Default Triggered | SYRS Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 04, 2024

Syros Pharmaceuticals (NASDAQ:SYRS) Rating Lowered to Sell at StockNews.com - MarketBeat

Nov 04, 2024
pulisher
Nov 04, 2024

SYRS (Syros Pharmaceuticals) Total Inventories : $0.00 Mil (As of Sep. 2024) - GuruFocus.com

Nov 04, 2024
pulisher
Nov 04, 2024

Syros Pharmaceuticals, Inc. announced that it expects to receive $10 million in funding from Incyte Corporation - Marketscreener.com

Nov 04, 2024
pulisher
Nov 03, 2024

Incyte Corporation and yros Pharmaceuticals Announce Global Target Discovery and Validation Collaboration Focused on Myeloproliferative Neoplasms - Marketscreener.com

Nov 03, 2024
pulisher
Nov 02, 2024

SYRSW (Syros Pharmaceuticals) 5-Year Dividend Growth Rate : 0.00% (As of Jun. 2024) - GuruFocus.com

Nov 02, 2024
pulisher
Nov 02, 2024

Syros Pharmaceuticals Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$1.43 loss in 3Q 2023) - Yahoo Finance

Nov 02, 2024
pulisher
Nov 01, 2024

Syros Pharmaceuticals (NASDAQ:SYRS) Issues Quarterly Earnings Results - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Earnings call: Syros Pharmaceuticals outlines tamibarotene progress By Investing.com - Investing.com South Africa

Nov 01, 2024
pulisher
Nov 01, 2024

Earnings call: Syros Pharmaceuticals outlines tamibarotene progress - Investing.com India

Nov 01, 2024
pulisher
Nov 01, 2024

Syros Pharmaceuticals Inc (SYRS) Q3 2024 Earnings Call Highlights: Strategic Focus on ... - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

HC Wainwright Reaffirms "Buy" Rating for Syros Pharmaceuticals (NASDAQ:SYRS) - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Syros Pharmaceuticals Inc (SYRS) Q3 2024 Earnings Call Highlight - GuruFocus.com

Nov 01, 2024
$70.39
price down icon 0.93%
$18.42
price down icon 1.07%
$38.25
price up icon 3.55%
$367.36
price up icon 0.83%
$194.56
price up icon 0.15%
$108.23
price up icon 5.96%
자본화:     |  볼륨(24시간):